Live Breaking News & Updates on Arcutis biotherapeutics

Stay informed with the latest breaking news from Arcutis biotherapeutics on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Arcutis biotherapeutics and stay connected to the pulse of your community

Financial Analysis: CNS Pharmaceuticals (NASDAQ:CNSP) vs. Arcutis Biotherapeutics (NASDAQ:ARQT)

Financial Analysis: CNS Pharmaceuticals (NASDAQ:CNSP) vs. Arcutis Biotherapeutics (NASDAQ:ARQT)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

California , United-states , Texas , Westlake-village , Houston , Arcutis-biotherapeutics , Arcutis-biotherapeutic , Houston-pharmaceuticals-inc , Pharmaceuticals-inc , Reata-pharmaceuticals-inc , Arcutis-inc , Arcutis-biotherapeutics-inc

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $26.56 Consensus Price Target from Analysts

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among […]

China , Arcutis-biotherapeutics , Masaru-matsuda , Needham-company , Tejara-capital-ltd , Securities-exchange-commission , Arcutis-biotherapeutics-inc , China-universal-asset-management-co , Deutsche-bank , Nasdaq , Goldman-sachs-group , Get-free-report

Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ALKS stock, giving a Buy rating yesterday. Chris Shibutani has giv...

Arcutis-biotherapeutics , Chris-shibutani , Goldman-sachs , Alkermes , Merck-company , Tipranks-premium ,

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 8% Higher

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report)’s share price was up 8% during trading on Thursday . The stock traded as high as $10.40 and last traded at $10.40. Approximately 304,052 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 4,965,885 shares. The stock had previously closed […]

Masaru-matsuda , Arcutis-biotherapeutics , Arcutis-biotherapeutics-company-profile , Tejara-capital-ltd , Citigroup-inc , Goldman-sachs-group , Deutsche-bank , Needham-company , Nasdaq , Arcutis-biotherapeutics-inc , Get-free-report , Capital-ltd

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Down 5.0% in March

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Down 5.0% in March
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Hong-kong , Arcutis-biotherapeutics , Masaru-matsuda , Dimensional-fund-advisors , Needham-company , Goldman-sachs-group , Arcutis-biotherapeutics-inc , Jpmorgan-chase-co , Hong-kong-ltd , Group-plc , Nasdaq , Arcutis-biotherapeutics-company-profile

2024-04-01 | NDAQ:SLGL | Press Release | Sol Gel Technologies Ltd

(2024-04-01 | NDAQ:SLGL) Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Canada , Israel , United-states , New-jersey , Arcutis-biotherapeutics , Padagis-closecurlyquote , Gilad-mamlok , Mori-arkin , Arcutis-closecurlydoublequote , Drug-administration , Company-closecurlyquote , Nasdaq

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4.6%

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) were down 4.6% during trading on Thursday . The stock traded as low as $10.17 and last traded at $10.30. Approximately 1,029,580 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 5,305,673 shares. The stock had previously closed […]

Hong-kong , China , Masaru-matsuda , Arcutis-biotherapeutics , Cantor-fitzgerald , Securities-exchange-commission , Nasdaq , Hong-kong-ltd , China-universal-asset-management-co , Arcutis-biotherapeutics-company-profile , Victory-capital-management-inc , Cape-investment-advisory-inc

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.7%

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report)’s stock price was down 7.7% during mid-day trading on Monday . The company traded as low as $10.06 and last traded at $10.29. Approximately 1,248,266 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 5,378,077 shares. The stock had previously […]

Hong-kong , Arcutis-biotherapeutics , Masaru-matsuda , Group-plc , Morgan-stanley , Arcutis-biotherapeutics-company-profile , Arcutis-biotherapeutics-inc , Nasdaq , Goldman-sachs-group , Hong-kong-ltd , Jpmorgan-chase-co , Needham-company

Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) investors will be delighted, with the company turning in some strong...

Arcutis-biotherapeutic , Arcutis-biotherapeutics ,

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Bought by Rubric Capital Management LP

Rubric Capital Management LP grew its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 3.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,034,530 shares of the company’s stock after buying an additional 150,000 shares during the period. Arcutis Biotherapeutics […]

Arcutis-biotherapeutics , Needham-company , Jennison-associates , Arcutis-biotherapeutics-inc , Marshall-wace , Vanguard-group-inc , Securities-exchange-commission , Nasdaq , Goldman-sachs-group , Blackrock-inc , Rubric-capital-management , Free-report